Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary Falcone is active.

Publication


Featured researches published by Mary Falcone.


Neuropsychopharmacology | 2015

Working Memory-Related Neural Activity Predicts Future Smoking Relapse

James Loughead; E. Paul Wileyto; Kosha Ruparel; Mary Falcone; Ryan Hopson; Ruben C. Gur; Caryn Lerman

Brief abstinence from smoking impairs cognition, particularly executive function, and this has a role in relapse to smoking. This study examined whether working memory-related brain activity predicts subsequent smoking relapse above and beyond standard clinical and behavioral measures. Eighty treatment-seeking smokers completed two functional magnetic resonance imaging sessions (smoking satiety vs 24 h abstinence challenge) during performance of a visual N-back task. Brief counseling and a short-term quit attempt followed. Relapse during the first 7 days was biochemically confirmed by the presence of the nicotine metabolite cotinine. Mean percent blood oxygen level-dependent (BOLD) signal change was extracted from a priori regions of interest: bilateral dorsolateral prefrontal cortex (DLPFC), medial frontal/cingulate gyrus, posterior cingulate cortex (PCC), and ventromedial prefrontal cortex. Signal from these brain regions and additional clinical measures were used to model outcome status, which was then validated with resampling techniques. Relapse to smoking was predicted by increased withdrawal symptoms, decreased left DLPFC and increased PCC BOLD percent signal change (abstinence vs smoking satiety). Receiver operating characteristic analysis demonstrated 81% area under the curve using these predictors, a significant improvement over the model with clinical variables only. The combination of abstinence-induced decreases in left DLPFC activation and reduced suppression of PCC may be a prognostic marker for poor outcome, specifically early smoking relapse.


Addiction Biology | 2014

Age‐related differences in working memory deficits during nicotine withdrawal

Mary Falcone; E. Paul Wileyto; Kosha Ruparel; Raphael T. Gerraty; Leah LaPrate; John A. Detre; Ruben C. Gur; James Loughead; Caryn Lerman

Nicotine withdrawal is associated with subtle working memory deficits that predict subsequent relapse. We examined the neural substrates underlying these processes in treatment‐seeking smokers, and explored the moderating influence of age on abstinence‐induced alterations in brain activity and performance. Sixty‐three smokers participated in two blood oxygen level‐dependent (BOLD) functional magnetic resonance imaging scans while performing a visual N‐back task on two separate occasions: smoking as usual and after 24 hours of biochemically confirmed abstinence (order counterbalanced). Abstinence (versus smoking) led to reduced accuracy, slower median correct response time and reduced BOLD signal change in the three a priori regions of interest: medial frontal/cingulate gyrus and right and left dorsolateral prefrontal cortex. Significant age × session effects were found for BOLD signal change in all three regions, as well as for withdrawal and craving; for all measures, abstinence effects were attenuated in smokers aged ≥50 years compared with those <50 years old. These results suggest that abstinence effects on neurocognitive function may be more pronounced for younger smokers, and may indicate a new avenue for research exploring mechanisms underlying age differences in smoking cessation success.


Nicotine & Tobacco Research | 2011

Association of the Nicotine Metabolite Ratio and CHRNA5/CHRNA3 Polymorphisms With Smoking Rate Among Treatment-Seeking Smokers

Mary Falcone; Christopher Jepson; Neal L. Benowitz; Andrew W. Bergen; Angela Pinto; E. Paul Wileyto; Don A. Baldwin; Rachel F. Tyndale; Caryn Lerman; Riju Ray

INTRODUCTION Genome-wide association studies have linked single-nucleotide polymorphisms (SNPs) in the CHRNA5/A3/B4 gene cluster with heaviness of smoking. The nicotine metabolite ratio (NMR), a measure of the rate of nicotine metabolism, is associated with the number of cigarettes per day (CPD) and likelihood of cessation. We tested the potential interacting effects of these two risk factors on CPD. METHODS Pretreatment data from three prior clinical trials were pooled for analysis. One thousand and thirty treatment seekers of European ancestry with genotype data for the CHRNA5/A3/B4 SNPs rs578776 and rs1051730 and complete data for NMR and CPD at pretreatment were included. Data for the third SNP, rs16969968, were available for 677 individuals. Linear regression models estimated the main and interacting effects of genotype and NMR on CPD. RESULTS We confirmed independent associations between the NMR and CPD as well as between the SNPs rs16969968 and rs1051730 and CPD. We did not detect a significant interaction between NMR and any of the SNPs examined. CONCLUSIONS This study demonstrates the additive and independent association of the NMR and SNPs in the CHRNA5/A3/B4 gene cluster with smoking rate in treatment-seeking smokers.


Neuropsychopharmacology | 2013

Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls.

Mary Falcone; Ryan M. Smith; Meghan J. Chenoweth; Abesh Kumar Bhattacharjee; John R. Kelsoe; Rachel F. Tyndale; Caryn Lerman

The integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment for neuropsychiatric conditions. Neuroimaging may provide a more sensitive early measure of treatment response in genetically defined patient groups, and could facilitate development of novel therapies based on an improved understanding of pathogenic mechanisms underlying pharmacogenetic associations. This review summarizes progress in efforts to incorporate neuroimaging into genetics and treatment research on major psychiatric disorders, such as schizophrenia, major depressive disorder, bipolar disorder, attention-deficit/hyperactivity disorder, and addiction. Methodological challenges include: performing genetic analyses in small study populations used in imaging studies; inclusion of patients with psychiatric comorbidities; and the extensive variability across studies in neuroimaging protocols, neurobehavioral task probes, and analytic strategies. Moreover, few studies use pharmacogenetic designs that permit testing of genotype × drug effects. As a result of these limitations, few findings have been fully replicated. Future studies that pre-screen participants for genetic variants selected a priori based on drug metabolism and targets have the greatest potential to advance the science and practice of psychiatric treatment.


Brain Stimulation | 2016

Transcranial Direct Current Brain Stimulation Increases Ability to Resist Smoking

Mary Falcone; Leah Bernardo; Rebecca L. Ashare; Roy H. Hamilton; Olufunsho Faseyitan; Sherry A. McKee; James Loughead; Caryn Lerman

BACKGROUND The ability to exert self-control over temptation is a fundamental component of smoking behavior change. Transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) has been shown to modulate cognitive control circuits. Although prior studies show that stimulation reduces cigarette craving and self-reported smoking, effects on ability to resist smoking have not been investigated directly. OBJECTIVES We assessed effects of a single 20-minute session of 1.0 mA anodal stimulation over the left DLPFC with cathodal stimulation over the right supra-orbital area (vs. sham stimulation) on ability to resist smoking in a validated smoking lapse paradigm. METHODS Twenty-five participants completed two tDCS sessions (active and sham stimulation) in a within-subject, double-blind, randomized and counterbalanced order with a 2-week washout period. Following overnight abstinence, participants received tDCS in the presence of smoking related cues; they had the option to smoke at any time or receive


Journal of Neuroimmune Pharmacology | 2016

Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Cheyenne E. Allenby; Kelly A. Boylan; Caryn Lerman; Mary Falcone

1 for every 5 minutes they abstained. After 50 minutes, they participated in a 1 hour ad libitum smoking session. Primary and secondary outcomes were time to first cigarette and cigarette consumption, respectively. RESULTS In multiple regression models, active tDCS (compared to sham) significantly increased latency to smoke (p = 0.02) and decreased the total number of cigarettes smoked (p = 0.014) during the session. CONCLUSION These findings suggest that acute anodal stimulation over the left DLPFC (with cathodal stimulation over the right supra-orbital area) can improve ability to resist smoking, supporting the therapeutic potential of tDCS for smoking cessation treatment.


Drug and Alcohol Dependence | 2013

No untoward effects of smoking cues in anti-smoking public service announcements

Mary Falcone; Caryn Lerman; Joseph N. Cappella; Paul Sanborn; Christopher Jepson; Andrew A. Strasser

Quitting smoking significantly reduces the risk of tobacco-related morbidity and mortality, yet there is a high rate of relapse amongst smokers who try to quit. Phenotypic biomarkers have the potential to improve smoking cessation outcomes by identifying the best available treatment for an individual smoker. In this review, we introduce the nicotine metabolite ratio (NMR) as a reliable and stable phenotypic measure of nicotine metabolism that can guide smoking cessation treatment among smokers who wish to quit. We address how the NMR accounts for sources of variation in nicotine metabolism including genotype and other biological and environmental factors such as estrogen levels, alcohol use, body mass index, or menthol exposure. Then, we highlight clinical trials that validate the NMR as a biomarker to predict therapeutic response to different pharmacotherapies for smoking cessation. Current evidence supports the use of nicotine replacement therapy for slow metabolizers, and non-nicotine treatments such as varenicline for normal metabolizers. Finally, we discuss future research directions to elucidate mechanisms underlying NMR associations with treatment response, and facilitate the implementation of the NMR as biomarker in clinical practice to guide smoking cessation.


The Journal of Nuclear Medicine | 2015

Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism

Jacob G. Dubroff; Robert K. Doot; Mary Falcone; Robert A. Schnoll; Riju Ray; Rachel F. Tyndale; Brody Al; Catherine Hou; Alexander Schmitz; Caryn Lerman

BACKGROUND Anti-smoking public service announcements (PSAs) often include smoking-related cues; however, visual drug cues can trigger acute cravings that may impede cognitive processing of the anti-smoking message. This experiment evaluated effects of smoking cues in PSAs on smoking urges, immediate smoking behavior, and persuasion measures in daily smokers. METHODS Three-hundred and eighteen non-treatment seeking smokers completed a single laboratory session during which they viewed sets of PSAs differentiated by presence of smoking cues (central to the PSAs argument, peripheral, or no cues) and argument strength (high versus low). After viewing the PSAs, participants completed self-report measures of smoking urges, attitudes toward quitting, self-efficacy, and intentions to quit smoking. Smoking behavior was recorded during a 1-h ad libitum smoking period immediately following PSA viewing and assessment. RESULTS There was a significant positive effect of argument strength on attitudes toward quitting smoking (p=0.012). There were no main effects of smoking cues or smoking cue by argument strength interactions on any of the outcome measures. CONCLUSIONS Visual smoking cues in PSAs do not increase urges to smoke, nor is there evidence that the inclusion of such cues impedes the recall or persuasive effects of anti-smoking arguments.


The Journal of Neuroscience | 2017

No Effect of Commercial Cognitive Training on Brain Activity, Choice Behavior, or Cognitive Performance

Joseph W. Kable; Kathleen Caulfield; Mary Falcone; Mairead H. McConnell; Leah Bernardo; Trishala Parthasarathi; Nicole J. Cooper; Rebecca L. Ashare; Janet Audrain-McGovern; Robert Hornik; Paul J. Diefenbach; Frank J. Lee; Caryn Lerman

The nicotine metabolite ratio (NMR), a stable measure of hepatic nicotine metabolism via the CYP2A6 pathway and total nicotine clearance, is a predictive biomarker of response to nicotine replacement therapy, with increased quit rates in slower metabolizers. Nicotine binds directly to nicotinic acetylcholine receptors (nAChRs) to exert its psychoactive effects. This study examined the relationship between NMR and nAChR (α4β2* subtype) availability using PET imaging of the radiotracer 2-18F-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-18F-FA-85380, or 2-18F-FA). Methods: Twenty-four smokers—12 slow metabolizers (NMR < 0.26) and 12 normal metabolizers (NMR ≥ 0.26)—underwent 2-18F-FA-PET brain imaging after overnight nicotine abstinence (18 h before scanning), using a validated bolus-plus-infusion protocol. Availability of nAChRs was compared between NMR groups in a priori volumes of interest, with total distribution volume (VT/fP) being the measure of nAChR availability. Cravings to smoke were assessed before and after the scans. Results: Thalamic nAChR α4β2* availability was significantly reduced in slow nicotine metabolizers (P = 0.04). Slow metabolizers exhibited greater reductions in cravings after scanning than normal metabolizers; however, craving was unrelated to nAChR availability. Conclusion: The rate of nicotine metabolism is associated with thalamic nAChR availability. Additional studies could examine whether altered nAChR availability underlies the differences in treatment response between slow and normal metabolizers of nicotine.


Psychopharmacology | 2012

μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief

Mary Falcone; Allison B. Gold; E. Paul Wileyto; Riju Ray; Kosha Ruparel; Andrew B. Newberg; Jacob Dubroff; Jean Logan; Jon Kar Zubieta; Julie A. Blendy; Caryn Lerman

Increased preference for immediate over delayed rewards and for risky over certain rewards has been associated with unhealthy behavioral choices. Motivated by evidence that enhanced cognitive control can shift choice behavior away from immediate and risky rewards, we tested whether training executive cognitive function could influence choice behavior and brain responses. In this randomized controlled trial, 128 young adults (71 male, 57 female) participated in 10 weeks of training with either a commercial web-based cognitive training program or web-based video games that do not specifically target executive function or adapt the level of difficulty throughout training. Pretraining and post-training, participants completed cognitive assessments and functional magnetic resonance imaging during performance of the following validated decision-making tasks: delay discounting (choices between smaller rewards now vs larger rewards in the future) and risk sensitivity (choices between larger riskier rewards vs smaller certain rewards). Contrary to our hypothesis, we found no evidence that cognitive training influences neural activity during decision-making; nor did we find effects of cognitive training on measures of delay discounting or risk sensitivity. Participants in the commercial training condition improved with practice on the specific tasks they performed during training, but participants in both conditions showed similar improvement on standardized cognitive measures over time. Moreover, the degree of improvement was comparable to that observed in individuals who were reassessed without any training whatsoever. Commercial adaptive cognitive training appears to have no benefits in healthy young adults above those of standard video games for measures of brain activity, choice behavior, or cognitive performance. SIGNIFICANCE STATEMENT Engagement of neural regions and circuits important in executive cognitive function can bias behavioral choices away from immediate rewards. Activity in these regions may be enhanced through adaptive cognitive training. Commercial brain training programs claim to improve a broad range of mental processes; however, evidence for transfer beyond trained tasks is mixed. We undertook the first randomized controlled trial of the effects of commercial adaptive cognitive training (Lumosity) on neural activity and decision-making in young adults (N = 128) compared with an active control (playing on-line video games). We found no evidence for relative benefits of cognitive training with respect to changes in decision-making behavior or brain response, or for cognitive task performance beyond those specifically trained.

Collaboration


Dive into the Mary Falcone's collaboration.

Top Co-Authors

Avatar

Caryn Lerman

Fox Chase Cancer Center

View shared research outputs
Top Co-Authors

Avatar

James Loughead

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

E. Paul Wileyto

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Leah Bernardo

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Rebecca L. Ashare

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Rachel F. Tyndale

Centre for Addiction and Mental Health

View shared research outputs
Top Co-Authors

Avatar

Kosha Ruparel

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Ruben C. Gur

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge